Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PTGX vs CRSP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTGX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

PTGX Overall Winner 6-Pillar Tally: PTGX 5 – 1 CRSP Matrix Metrics: PTGX 7 – 3 CRSP

As of Nov 16, 2026, Protagonist Therapeutics, Inc (PTGX) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PTGX carries a Unified Composite Score of 32.6/100 (SELL) at $125.40 (36.9x Forward P/E, 58.6% operating margin), whereas CRSP carries 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin).

  • Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. PTGX 32.6/100 SELL), PTGX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (58.6% vs. -2058.6% operating margin) and revenue trajectory (+5723.6% vs. +1325.1% YoY).
  • Technical & Structure Timing Caution: PTGX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.0); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PTGX vs CRSP
PTGX NASDAQ Head-to-Head Winner
Protagonist Therapeutics, Inc
Pharmaceutical Preparations
$125.40
-4.24% 1D
Market Cap $8.7B
TTM Revenue $552M
Forward P/E 36.9x
Beta / 30D Vol 1.02β · 35% Vol
Unified Composite Score
32.6 / 100 SELL
Tech 17.0 Fund 44.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.6%), weak momentum, RSI 33
RSI-14: 33.0 · SMA20: $137.74 · SMA50: $139.89
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 30
RSI-14: 29.6 · SMA20: $48.84 · SMA50: $51.79

6-Pillar Scorecard Institutional Category Breakdown (PTGX 5 – 1 CRSP)

Columns: Metric · PTGX · CRSP
1. Valuation Multiples CRSP
Forward P/E 36.9x 23.4x
Trailing P/E 28.1x 23.4x
PEG Ratio N/M N/M
EV / Revenue 14.8x N/M
2. Growth & Scale PTGX
Revenue Growth (YoY) +5723.6% +1325.1%
Earnings Growth (YoY) +351.3% +0.0%
TTM Revenue (USD) $552M $25M
Market Cap $8.7B $4.1B
3. Profitability & Quality PTGX
Gross Margin 99.8% N/A
Operating Margin 58.6% -2058.6%
Net Profit Margin 62.0% 0.0%
Return on Equity (ROE) 39.6% -25.6%
4. Balance Sheet & Cash Flow PTGX
Cash Generation (TTM) $109M -$378M
Cash Flow Margin 19.8% N/A
Net Cash / Leverage $490M Net Cash $588M Net Debt (0.47x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PTGX
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 39.4% (3rd %ile) 97.8% (52nd %ile)
Put/Call OI Skew N/A 0.65x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat PTGX
OpEx & R&D Intensity 41.2% of Rev ($227M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PTGX (7) vs CRSP (3)
Institutional Metric PTGX CRSP Criterion Row Edge
Market Capitalization
Scale
$8.7B $4.1B Larger Scale PTGX
Trailing P/E Ratio
Valuation
28.1x 23.4x Lower Multiple CRSP
Forward P/E Ratio
Valuation
36.9x 23.4x Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+5723.6% +1325.1% Higher Growth PTGX
Operating Margin (TTM)
Profitability
58.6% -2058.6% Higher Margin PTGX
Net Profit Margin
Profitability
62.0% 0.0% Higher Margin PTGX
Return on Equity (ROE)
Capital Efficiency
39.6% -25.6% Higher ROE PTGX
52-Week Range Position
Momentum
58% ($77–$161) 1% ($40–$63) Stronger Trend PTGX
Beta / 30D Volatility
Risk Regime
1.02β · 35% Vol 1.85β · 60% Vol Lower Realized Risk PTGX
Unified Institutional Score
Composite Signal
32.6 / 100 (SELL) 44.7 / 100 (HOLD) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$552M $25M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$109M ($490M Net Cash) -$378M ($588M Net Debt (0.47x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTGX +14.94 pp
PTGX: -2.6% · CRSP: -17.54%
3M Horizon PTGX +3.03 pp
PTGX: -20.3% · CRSP: -23.33%
6M Horizon PTGX +40.85 pp
PTGX: +24.48% · CRSP: -16.37%
1Y Horizon PTGX +71.19 pp
PTGX: +50.65% · CRSP: -20.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PTGX Revenue CRSP Revenue PTGX Op. Margin CRSP Op. Margin Margin Leader
FY2018 $30M $0M -136.7% -5087.8% PTGX
FY2019 $0M $290M -34857.6% 16.1% CRSP
FY2020 $30M $0M -225.4% -49295.5% PTGX
FY2021 $30M $910M -460.0% 40.8% CRSP
FY2022 $30M $0M -494.2% -56190.4% PTGX
FY2023 $60M $370M -156.1% -60.0% CRSP
FY2024 $430M $40M 58.2% -1250.4% PTGX
FY2025 $50M $0M -343.6% -18933.6% PTGX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PTGX CONSOLIDATION
64d in phase · OBV NEUTRAL
Current IV 39.4%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PTGX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PTGX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $8.7B market capitalization and 58.6% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($227M)
90D Engineering Disclosures 0 Published
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PTGX vs CRSP Key Questions & Quantitative Answers

As of Nov 16, 2026, Protagonist Therapeutics, Inc (PTGX) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PTGX carries a Unified Composite Score of 32.6/100 (SELL) at $125.40 (36.9x Forward P/E, 58.6% operating margin), whereas CRSP carries 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin). Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. PTGX 32.6/100 SELL), PTGX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (58.6% vs. -2058.6% operating margin) and revenue trajectory (+5723.6% vs. +1325.1% YoY). Technical & Structure Timing Caution: PTGX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.0); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PTGX leads the Growth & Scale pillar: PTGX posts +5723.6% YoY revenue growth and +351.3% YoY earnings growth on $552M TTM revenue (99.8% gross margin, 58.6% operating margin), compared with CRSP at +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PTGX cumulative revenue shifted +66.7% while CRSP shifted -86.2%. In operating R&D and SG&A reinvestment, PTGX deploys 41.2% of Rev ($227M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRSP.

CRSP screens cheaper on headline valuation multiples. PTGX trades at 36.9x Forward P/E, 28.1x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (19.8% FCF margin), whereas CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTGX (39.6% ROE) versus CRSP (-25.6% ROE) capital efficiency.

In options market volatility and institutional positioning, PTGX carries 39.4% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.02β · 35% Vol realized risk). By comparison, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.